• Publications
  • Influence
Premature mortality in patients with Addison's disease: a population-based study.
TLDR
It is observed that the risk ratio for death was more than 2-fold higher in patients with Addison's disease compared with the background population, and cardiovascular, malignant, and infectious diseases were responsible for the higher mortality rate. Expand
Dose‐ranging study with the glucokinase activator AZD1656 in patients with type 2 diabetes mellitus on metformin
To investigate the effect of glucokinase activator AZD1656 on glycated haemoglobin (HbA1c) as an add‐on to metformin in patients with type 2 diabetes.
Dose‐ranging study with the glucokinase activator AZD1656 as monotherapy in Japanese patients with type 2 diabetes mellitus
To assess the glucose‐lowering effects of monotherapy with the glucokinase activator AZD1656 in Japanese patients with type 2 diabetes mellitus.
Ticagrelor in Patients with Stable Coronary Disease and Diabetes.
TLDR
In patients with stable coronary artery disease and diabetes without a history of myocardial infarction or stroke, patients who received ticagrelor plus aspirin had a lower incidence of ischemic cardiovascular events but a higher incidence of major bleeding than those who received placebo plus aspirin. Expand
Effect of Tenapanor on Serum Phosphate in Patients Receiving Hemodialysis.
TLDR
Tenapanor treatment resulted in statistically significant, dose-dependent reductions in serum phosphate concentrations in patients with hyperphosphatemia receiving hemodialysis, and diarrhea was the most common adverse event. Expand
Safety, pharmacokinetics and pharmacodynamics of multiple‐ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus
To assess the safety, pharmacokinetics and pharmacodynamics of multiple‐ascending doses of the novel glucokinase activator AZD1656 in patients with type 2 diabetes mellitus (T2DM).
Tolerability, pharmacokinetics, and pharmacodynamics of the glucokinase activator AZD1656, after single ascending doses in healthy subjects during euglycemic clamp.
TLDR
The results suggest no ethnic differences in AZD1656 tolerability, pharmacokinetics or pharmacodynamics are suggested, and the drug has the potential to deliver effective glucose-lowering in Type 2 diabetes mellitus. Expand
Visceral Fat and Novel Biomarkers of Cardiovascular Disease in Patients With Addison's Disease: A Case‐Control Study
TLDR
The prevalence of MetS was increased and several biomarkers of cardiovascular disease were adversely affected in patients with AD, and VAT was not increased, despite higher cortisol exposure. Expand
A phase 1 study of the safety, tolerability, pharmacodynamics, and pharmacokinetics of tenapanor in healthy Japanese volunteers
TLDR
Tenapanor treatment reduced absorption of intestinal sodium and phosphate from the gut in Japanese adults and had minimal systemic exposure and was well tolerated. Expand
Glucokinase activators AZD6370 and AZD1656 do not affect the central counterregulatory response to hypoglycemia in healthy males.
TLDR
The central nervous system-mediated counterregulatory response during GKA-induced hypoglycemia was preserved, whereas the glucagon response was attenuated; the latter was possibly mediated by a local pancreatic effect (intraislet hyperinsulinemia) rather than by impairment of the central nervous System-mediated response. Expand
...
1
2
...